BioLife Solutions: CMO Todd Berard sold shares

What happened Todd Berard, chief marketing officer of BioLife Solutions, reported awards and dispositions tied to the Oct 6, 2026 merger. The Form 4 shows acquisitions of 38,198 and 40,192 shares (restricted stock awards), 46,170 shares disposed to cover tax withholding at $38.61 for $1,782,624, and 194,786 shares disposed to the issuer in connection with the merger.

Key details

• Transaction date(s) and price(s): Oct 6, 2026. Acquired (A): 38,198 and 40,192 shares (no per-share price listed). Disposed (F): 46,170 shares at $38.61 ($1,782,624). Disposed (D): 194,786 shares (no per-share price listed). Filing date: Oct 8, 2026.
• Shares owned after the transaction: not stated in the filing excerpt provided.
• Footnotes: F1 — each outstanding BioLife share was converted at the merger into $11.25 in cash plus 0.1442 shares of Repligen common stock. F2 and F3 — the restricted stock awards were granted under the 2023 Omnibus Performance Incentive Plan and vested immediately prior to the merger at approximately 200% based on total shareholder return measurements. F4 — 46,170 shares were withheld to cover tax withholding obligations in connection with vesting.
• Filing timeliness: the Form 4 was filed Oct 8, 2026 reporting Oct 6, 2026 transactions (the filing shows these dates).

Why it may matter

• The filing shows restricted stock vested immediately before the merger and that a portion of shares were withheld to satisfy tax withholding (a cashless withholding).
• Other disposed shares were surrendered to the issuer as part of the merger consideration described in the filing.
• A filing does not show why the insider traded or why the company acted.